

ACRA 2013 2nd quarter

NEWSLETTER

Alabama Cancer Registrars Association 2012-2013 Officers and Committee Chairs

President-Lou Ellen Marchman
President Elect-Joanne Powers
Vice President-Paula Wyatt
Secretary-Wendy Richardson
Treasurer-Belinda Limbaugh
Treasurer-Elect-Kelly Evers
Historian/Parliamentarian-DeeAnn Harris
Immediate Past President-Priscilla Foster

Education-Pamela Tillman
Bylaws-Judy Smith
Ways & Means-Joanne Powers
Membership-Connie Jensen
Donation-Priscilla Foster
Nominating-Sheila Grant
Ballot-Diane Hadley
Website-Shantel Dailey

A Message from our President.....

Greeting from Lou Ellen Marchman, ACRA President 2012-13

I hope you all had a good National Cancer Registrar's week. Time is going by so fast! It is hard to believe my year as president is half over.


Pam Tillman and her Education Committee began work on this year's meeting back in January. They have found us a very nice (and affordable) meeting location. I really appreciate their getting to work on this so quickly. It was such a relief to have the location taken care of early. This year's meeting will be September 26 and 27th in Daphne, AL. Additional details on the meeting location can be found later in this newsletter.

I would like to encourage those of you who attend NCRA this year to share information and pictures with the association. Due to ACRA's bank account being low, we do not have the money to send a representative to NCRA as we normally do. The Board of Directors is watching our bank account closely. We hope to save/raise more money for next year.

I hope you all are taking time to get outside and enjoy the nice spring weather. I like to get outside and walk at lunch. It helps me clear my head. I know some of you do the same thing. I find that I get more work done and do a better job if I take a little time to get outside away from my computer.

If you are not already involved on a committee you are welcome to volunteer your time. Also, please begin to think about running for office next year. Feel free to contact me if you have any suggestions, questions or would like to volunteer to help out in some way.

You can email me at: lemarchman@hotmail.com





ANNUAL MEETING INFORMATION

**The date has been set!!!
Mark your calendars!!!**

**The place has been booked!!!
Make your reservations!!!**

**ALABAMA CANCER REGISTRAR'S ASSOCIATION
2013 ANNUAL EDUCATIONAL CONFERENCE
"TAMING THE JUNGLE OF DATA"
SEPTEMBER 26 AND 27, 2013
HILTON GARDEN INN MOBILE EAST BAY/DAPHNE**

29546 North Main Street
DAPHNE, AL 36526
(251) 625-0020

Rooms are \$109 per night
www.hgidaphne.com
Group code – ALC

Reservations must be made by AUGUST 28, 2013 to ensure group rate

More information on the actual program will be provided at a later date!
Still working on the details!!

**We will be having raffles again this year!! Doesn't have to be a basket!!
Use your imagination!**

**We will be needing items for the goody bags so start asking your facility
and anyone else you know that would donate!! Need at least 65 of each
item!**

**Pens, pencils, notepads, hand sanitizers, Band-Aids, koozies, finger nail
files, highlighters, anything you can think of...we luv our goodies!!**

Please visit the following site for more information. <http://alabamacra.org/id16.html>



Montgomery Class



Birmingham Class



A HERO amongst us!!!

Joanne Powers serves as the cancer registry coordinator at Flowers Hospital in Dothan, where she records data on cancer patients that physicians use to make improvements to cancer therapies and support treatment. In 2010 she was diagnosed with Multiple Sclerosis and soon after began struggling to walk. Her fellow employees speak of how she inspired them by dedicating herself to overcoming her physical challenges while remaining dedicated to her duties. As a result of her perseverance, she is now walking unassisted. Ms. Powers is also involved in her community. She helped bring the first Multiple Sclerosis walk to Dothan, which raised more than \$25,000. As president-elect of the Alabama Cancer Registrar Association, she is working to bring the state meeting to Dothan and hopes to raise money for Relay for Life at the event. Ms. Powers' positive spirit has inspired her co-workers. As one recently said, "She supports those who cannot stand, pushes for those that cannot walk, campaigns for those who have lost their voice, believes in those who have lost their faith and encourages the discouraged."



Congratulations!

We are ALL so PROUD of you Joanne and the strength you exude as you face these challenges. -ACRA Members

<http://www.alaha.org/media.aspx?id=12129>

<http://www.wtv.com/home/headlines/Local-Hospital-Heros-191897951.html>





SEER*Rx Interactive Antineoplastic Drugs Database

Data last updated: January 23, 2013

[<< SEER*Rx Home](#)
[Questions? Ask a SEER Registrar](#)



Drugs (1)

Regimens (0)

Trastuzumab

Drug Information

Generic Name

Trastuzumab

Brand Name

Anti-c-erbB2 monoclonal antibody
 Anti-erbB2 monoclonal antibody
 Anti-HER2 monoclonal antibody
 Anti-HER2/c-erbB2 monoclonal antibody
 Anti-p185-HER2 monoclonal antibody
 HER2 Mab
 HER2 monoclonal antibody
 HER2/neu Mab
 HER2/neu monoclonal antibody
Herceptin

Abbreviation

None

Category

Biologic therapy (BRM, immunotherapy)

Subcategory

Targeted therapy--epidermal growth factor receptor

NSC Number


688097

Primary Site

Breast
 colorectal
 lung
 ovarian
 pancreatic
 prostate cancer

Remarks

JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Herceptin is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Herceptin as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this as chemotherapy. Phase II (breast, colorectal, lung) Phase III (ovarian, prostate) Anti HER-2 monoclonal antibody. FDA approved for use on breast cancer. Genentech, NCI. FDA granted approval 10/2010 for Herceptin in combination with cisplatin and fluoropyrimidine (either capecitabine or 5-FU) for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal (GE) junction adenocarcinoma who have not received prior treatment for metastatic disease.



A Snapshot of Esophageal Cancer



Incidence and Mortality

Esophageal cancer consists of two primary types, [adenocarcinoma](#) and [squamous cell carcinoma](#). Of these two types, adenocarcinoma of the esophagus is more common than squamous cell carcinoma in the United States due to its rising incidence, particularly in white men. Regardless of race or ethnicity, men have higher incidence and mortality rates than do women. Historically, esophageal cancer mortality rates for African-American men have been higher than those for white men, although a steady decline over the past two decades coupled with increasing rates in whites has recently reversed this trend. The downward trend in mortality has not been observed for other racial/ethnic groups.

[Risk factors](#) for esophageal cancer include tobacco use, heavy alcohol use, [Barrett esophagus](#), [gastric reflux](#), increasing age, and being male. There is no standard or routine [screening](#) test for esophageal cancer. Standard treatment options for esophageal cancer include surgery, [radiation therapy](#), [chemotherapy](#), [laser therapy](#), and [electrocoagulation](#).

It is estimated that approximately \$1.3 billion¹ is spent in the United States each year on esophageal cancer treatment.

Source for incidence and mortality data: Surveillance, Epidemiology, and End Results (SEER) Program and the National Center for Health Statistics. Additional statistics and charts are available at the [SEER](#) Web site.

¹ [Cancer Trends Progress Report](#), in 2010 dollars.

Trends in NCI Funding for Esophageal Cancer Research


The National Cancer Institute's (NCI) investment² in [esophageal cancer research](#) increased from \$22.3 million in fiscal year (FY) 2007 to \$33.0 million in FY 2011. In addition to this funding, NCI supported \$6.0 million in esophageal cancer research in FY 2009 and 2010 using funding from the American Recovery and Reinvestment Act (ARRA).³

Source: NCI [Office of Budget and Finance](#).


² The estimated NCI investment is based on funding associated with a broad range of peer-reviewed scientific activities. For additional information on research planning and budgeting at the National Institutes of Health (NIH), see [About NIH](#).

³ For more information regarding ARRA funding at NCI, see [Recovery Act Funding at NCI](#).


U.S. Esophageal Cancer Incidence



U.S. Esophageal Cancer Mortality



NCI Esophageal Cancer Research Investment




Examples of NCI Activities Relevant to Esophageal Cancer

- The [Prevention Agents Program](#) provides scientific and administrative oversight for [chemoprevention](#) agent development from preclinical research to early [phase I clinical trials](#). The program is currently supporting research on several agents for potential chemoprevention of esophageal cancer.
- The [Epidemiology of Esophageal Cancer Consortia](#) include the Asian Barrett's Consortium and the International Barrett's and Esophageal Adenocarcinoma Consortium (BEACON), which were formed to enhance international collaborations in research into the [etiology](#) and prevention of Barrett esophagus and esophageal adenocarcinoma.
- NCI supports early-phase clinical trials of targeted, personalized cancer regimens through the [Accelerating Clinical Trials of Novel Oncologic Pathways \(ACTNOW\)](#) program, including a [phase II trial](#) in patients with advanced gastric and [gastroesophageal junction carcinoma](#).
- The [Phase III Randomized Study of Radiotherapy, Paclitaxel, and Carboplatin with versus without Trastuzumab in Patients with HER2-Overexpressing Esophageal Adenocarcinoma](#) is investigating whether adding targeted therapy to chemotherapy and radiation will reduce disease recurrence and extend survival in people with [HER2-positive](#) esophageal cancer.
- The [Esophagus Cancer Modeling](#) project, conducted by the Cancer Intervention and Surveillance Modeling Network (CISNET), explores the incidence and mortality of esophageal adenocarcinoma, hypothetical screening strategies, chemotherapy, and endoscopic therapy.
- Seven gastrointestinal-cancer-specific [Specialized Programs of Research Excellence \(SPORs\)](#) focus on translational research on the gastrointestinal system, including esophageal cancer.

Additional Resources for Esophageal Cancer

- The [What You Need To Know About™ Cancer of the Esophagus](#) booklet contains information on diagnosis and staging, treatment, supportive care and nutrition, and taking part in research studies. Information specialists also can answer questions about cancer at 1-800-4-CANCER.
- The NCI [Esophageal Cancer Home Page](#) provides up-to-date information on esophageal cancer treatment, prevention, genetics, causes, screening, testing, and related topics.
- Information on treatment options for esophageal cancer is available from [PDQ](#), NCI's comprehensive cancer database.
- [Clinical trials for esophageal cancer](#) can be found in NCI's list of clinical trials.

NCI Esophageal Cancer Research Portfolio



Percentage of Total Dollars by Scientific Area
Fiscal Year 2011

Data source: NCI Funded Research Portfolio. Only projects with assigned [scientific area codes](#) are included. A description of relevant research projects can be found on the [NCI Funded Research Portfolio Web site](#).

Selected Advances in Esophageal Cancer Research

- A genomic analysis found that inherited mutations in [three genes were associated with increased risk of Barrett esophagus and esophageal adenocarcinoma](#). Published July 2011.
- A [transgenic mouse](#) model was developed that provides new insights into the [molecular and cellular origins of Barrett esophagus and esophageal adenocarcinoma](#). Published January 2012.
- Researchers identified two new [microRNA markers associated with progression of Barrett esophagus](#) to esophageal adenocarcinoma. Published February 2012.
- Researchers discovered that [two signaling pathways interact during development of esophageal adenocarcinoma](#), suggesting that patients might benefit from a two-pronged therapy approach. Published March 2012.
- Click [here](#) to access selected free full-text journal articles on advances in NCI-supported research relevant to esophageal cancer. Click [here](#) to search for additional scientific articles or to complete a [search tutorial](#) on PubMed.

A Special Announcement from The CoC Source

[COC HOME](#)[CONTACT US](#)[MANAGE YOUR SUBSCRIPTION](#)[FORWARD TO A FRIEND](#)

March 4, 2013

New Videos on CoC Standards Now Available

The CoC has launched a new series of free videos, created to assist you in understanding and interpreting the CoC Standards. This series includes an introduction video, two videos describing the Eligibility Requirements, and an additional 26 videos describing select Standards. Each video begins with the definition of the Standard, describes the requirements for meeting the Standard, and concludes with best practice information. These videos can be viewed individually, or shown during staff meetings to assist in clarifying Standards requirements. We hope that you and other members of your cancer committee find these videos useful as you work to implement and maintain compliance with the CoC Standards.

Introducing...

Meet ASCR New Information Systems Manager



Hello, everyone! My name is Teresa Trailer. I have been employed at ASCR for almost 2 months now. I love working with analytics, statistics and information system management. I am a problem-solver by nature and hope to be a great asset to all of you. I have been employed with State for about 3 years. I received her B.S. in Human Resource Administration at Faulkner University and my M.S. in Human Resource Management at Troy University Montgomery. In my role at ASCR, I will be responsible for the administration of ASCR information systems to include providing technical support, updating software programs related to RegPlus Suite, and disseminate information for cancer reporting and advanced cancer registry activities.

I am here to make your job a little easier! So, please don't hesitate to contact me. I can be reached at 334-206-5918. My email address is teresa.trailer@adph.state.al.us. I look forward to working with you. One thing I would like to share with you... I am NOT an Alabama fan! **WAR EAGLE!!**



Alabama Statewide Cancer Registry (ASCR)



NAACCR Version 13 Conversion

In accordance with the data transmission standards set by the and North American Association of Central Registries (NAACCR) and Centers for Disease Control and Prevention (CDC) National Program of Cancer Registries (NPCR), the ASCR will be converting its database to NAACCR Version 13 for 2013 data submission. Conversion from NAACCR Version 12.2 to NAACCR Version 13 is expected to be completed by early June, 2013.

The major difference from earlier versions of NAACCR to Version 13 is the ability to move to interoperable geographic area codes. All Registry Plus software conversions will populate these new country and state data items automatically as noted in the table below:

Standards Volume II, Version 13 New Country and State Data Items			
Data Item Name	Item #	Column	Source of Standard
Addr at DX--Country	102	436-438	NAACCR
Addr Current--Country	1832	439-441	NAACCR
Birthplace--Country	254	444-446	NAACCR
Birthplace--State	252	442-443	NAACCR
Followup Contact--Country	1847	447-449	NAACCR
Place of Death--Country	1944	452-454	NAACCR
Place of Death--State	1942	450-451	NAACCR

Other RegPlus Program Updates

- NAACCR 13.0- compliant versions of **Web Plus** and **Abstract Plus** will be available by early June, 2013.
- **GenEDITS 1.2.6** has been released for compatibility with NAACCR version 13.0 data standards. The newest releases can be found at <http://www.cdc.gov/cancer/npcr/tools/edits/versionanddownload.htm>.
- The **Web Plus** website address has been changed. The new Web Plus URL is <https://webplus.adph.state.al.us>. Please check the ASCR website regularly for more updates on 2013 data submission.

2013 Data Submission from Reporting Facilities

- All users should finish 2012 data submission before updating the software for 2013 data submission.

For Abs Plus users, since there are only minor changes in V13, current version of Abs Plus can be used for 2013 data submission. However, when the ASCR sends out the V13 installation CD, all the users should update to it as soon as possible. If any user is still use version other than 3.2.1.0, please contact the ASCR to update your Abs Plus immediately.



Celebrating at a Cullman County webinar:


Rekha Khatri, MPH, CTR
 Connie Jensen, RHIT, CTR
 Kristi Lloyd
 Cindy Johnson, CTR
 Glenda Wilson, RHIA, CTR
 Judy Walker
 Diane Hadley, BS, RHIT, CTR
 Barbara Roberts, CTR
 Kelly Evers, CTR
 Paula Wyatt, Registry Coordinator


Celebrating Our Profession



NCRA Week at UAB- On Wednesday,
 they all went out to lunch at
 Newk's as a group and on Friday,
 the HIM department celebrated
 with a Taco Bar for the entire
 HIM Dept. (appr. 80 employees).
 Regina Dillard, MSHI, CTR, RHIT,
 Manager

Lelia Edwards, MSHI, CTR, RHIT
 Yolanda Gatson, CTR, RHIT
 Chammie Katz, CTR, RHIT
 Patricia Caldwell Jamieson, CTR, RHIT
 Jacqueline Miles, CTR, RHIT, LPN
 Nadine Kelly, RHIT
 Laronda Reese
 Felecia Butts Fields
 Rachel Brown
 Wanda Godfrey





The Cancer Registry display at the VA in Birmingham.

Registrars are:

Pamela Ansari, RHIT, CTR

Karen Hood, RHIA, CTR

Errica Hunter, RHIA, CTR

A word from your Vice President....

Hello everyone. I hope everyone enjoyed the last newsletter and hopefully enjoy this one as well. I actually am enjoying working on the newsletters. In the beginning I was quite intimidated and worried that I wouldn't do the job well. Thank you to everyone on your feedback and comments regarding the newsletter, I greatly appreciate all your input.

If you have any upcoming events or information you want to share, please email me and I will be glad to include it.

Again, thank you to everyone for all you do to make our profession and association great!!!

Paula Wyatt

Paula_wyatt@gadsdenregional.com

Happy Birthday!



April

16-Chad Brown



May

5-Rebecca Thomas

12-Diane Lolley

15-Glenda Wilson

17-Susan McMillan

**28- Kimberly Spain
and Pamela Ansari**

**30-Ruth Monella
and Tamara Scott**



June

8- Judy Smith

12-Belinda Limbaugh

**18-Crystal Morton and
Linda Halasz**

25-Karen Moulds

26- Paula Wyatt

27-Shantel Dailey



July

8-Shirley Williams

**19- Xuejen Shen and
Barbara Roberts**

23-Carol Kennemur

28-Shri Merriweather

